⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GLUE News
Monte Rosa Therapeutics, Inc. Common Stock
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
GLUE
Form 8-K
sec.gov
GLUE
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
globenewswire.com
GLUE
Gluware Unveils Industry-First Agentic Feature-Aware Vulnerability Detection and Network Remediation
prnewswire.com
GLUE
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
GLUE
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
globenewswire.com
GLUE
Form 8-K
sec.gov
GLUE
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
globenewswire.com
GLUE
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
globenewswire.com
GLUE
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
globenewswire.com
GLUE